RareCan is a direct-to-patient clinical trial platform, harnessing the power of patients and data aiming to reduce costs and increase the success rate of rare cancer trials for the $143bn global cancer drug market. Raising to grow the team and develop platform capabilities.
Every day around 1000 people in the UK are told they have cancer. For an est. 1 in 5 their cancer is too rare for the best treatment to be clear because of insufficient research.
We believe there's an opportunity to change this. Although treatments targeting rare cancers represent 63% of the oncology trials in 2020, recruiting enough patients to test them is a challenge for the $49bn Contract Research Organisation (CRO) industry that supports trial delivery.
RareCan aims to be a solution to this problem. RareCan is a direct-to-patient clinical trial platform, bringing together patients and their clinical, laboratory and genetic data, aiming to increase speed of recruitment, reduce screen failure and increase retention rates for trials.
We have recruited over 800 people with rare cancers; received NHS ethics approval for the process of collecting samples for our BioResource and started genetic sequencing of cancer samples from our members; we have a commercial contract agreed and a confidentiality agreement in place with 3 of the world's largest CRO's.
We are raising funds with the aim of growing our team, expanding our marketing and developing our platform to provide trial recruitment services to help accelerate the rate at which new treatments are made available with the aim of helping to improve outcomes for millions of people living with rare cancers.